The DOI matches its Crossref record; 228 of the 228 references it cites were found in a registry or an index.
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Open accessAbstract
The medical history of cancer began millennia ago. Historical findings of patients with cancer date back to ancient Egyptian and Greek civilizations, where this disease was predominantly treated with radical surgery and cautery that were often ineffective, leading to the death of patients. Over the centuries, important discoveries allowed to identify the biological and pathological features of tumors, without however contributing to the development of effective therapeutic approaches until the end of the 1800s, when the discovery of X-rays and their use for the treatment of tumors provided the first modern therapeutic approach in medical oncology. However, a real breakthrough took place after the Second World War, with the discovery of cytotoxic antitumor drugs and the birth of chemotherapy for the treatment of various hematological and solid tumors. Starting from this epochal turning point, there has been an exponential growth of studies concerning the use of new drugs for cancer treatment. The second fundamental breakthrough in the field of oncology and pharmacology took place at the beginning of the '80s, thanks to molecular and cellular biology studies that allowed the development of specific drugs for some molecular targets involved in neoplastic processes, giving rise to targeted therapy. Both chemotherapy and target therapy have significantly improved the survival and quality of life of cancer patients inducing sometimes complete tumor remission. Subsequently, at the turn of the third millennium, thanks to genetic engineering studies, there was a further advancement of clinical oncology and pharmacology with the introduction of monoclonal antibodies and immune checkpoint inhibitors for the treatment of advanced or metastatic tumors, for which no effective treatment was available before. Today, cancer research is always aimed at the study and development of new therapeutic approaches for cancer treatment. Currently, several researchers are focused on the development of cell therapies, anti-tumor vaccines, and new biotechnological drugs that have already shown promising results in preclinical studies, therefore, in the near future, we will certainly assist to a new revolution in the field of medical oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., & McPhail, A. T. (1971) · Journal of the American Chemical Society · doi:10.1021/ja00738a045 · Cited by 4,073
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Microtubules as a target for anticancer drugs
Jordan, M. A., & Wilson, L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1317 · Cited by 4,000
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Combination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Ferrara, N., & Henzel, W. J. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92678-8 · Cited by 2,268
Wall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., McPhail, A. T., & Sim, G. A. (1966) · Journal of the American Chemical Society · doi:10.1021/ja00968a057 · Cited by 2,258
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Chemotherapy and the war on cancer
Chabner, B. A., & Roberts, T. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1529 · Cited by 2,154
Nicholson, R. I., Gee, J. M. W., & Harper, M. E. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,143
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,961
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Farber, S., Diamond, L. K., Mercer, R. D., Sylvester, R. F., & Wolff, J. A. (1948) · New England Journal of Medicine · doi:10.1056/nejm194806032382301 · Cited by 1,806
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
VÉZINA, C., KUDELSKI, A., & SEHGAL, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,687
Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2574 · Cited by 1,634
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Fluorinated pyrimidines, a new class of tumour-inhibitory compounds
HEIDELBERGER, C., CHAUDHURI, N. K., DANNEBERG, P., MOOREN, D., GRIESBACH, L., DUSCHINSKY, R., SCHNITZER, R. J., PLEVEN, E., & SCHEINER, J. (1957) · Nature · doi:10.1038/179663a0 · Cited by 1,603
The EGFR family and its ligands in human cancer
Yarden, Y. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00230-1 · Cited by 1,587
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Akinyemiju, T. F., Al Lami, F. H., Alam, T., Alizadeh-Navaei, R., Allen, C., Alsharif, U., Alvis-Guzman, N., Amini, E., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2706 · Cited by 1,518
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,490
Combination Chemotherapy in the Treatment of Advanced Hodgkin's Disease
DEVITA, V. T., SERPICK, A. A., & CARBONE, P. P. (1970) · Annals of Internal Medicine · doi:10.7326/0003-4819-73-6-881 · Cited by 1,436
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360
Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337
Rosenberg, S. A., Aebersold, P., Cornetta, K., Kasid, A., Morgan, R. A., Moen, R., Karson, E. M., Lotze, M. T., Yang, J. C., Topalian, S. L., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008303230904 · Cited by 1,318
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Hegg, R., Tausch, C., Seo, J. H., Tsai, Y.-F., Ratnayake, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt182 · Cited by 1,264
Polyamines and cancer: old molecules, new understanding
Gerner, E. W., & Meyskens, F. L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1454 · Cited by 1,159
Blanke, C. D., Rankin, C., Demetri, G. D., Ryan, C. W., von Mehren, M., Benjamin, R. S., Raymond, A. K., Bramwell, V. H. C., Baker, L. H., Maki, R. G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.4452 · Cited by 1,073
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057
Cyclophosphamide and cancer: golden anniversary
Emadi, A., Jones, R. J., & Brodsky, R. A. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.146 · Cited by 1,050
Proteasome inhibitors in cancer therapy
Manasanch, E. E., & Orlowski, R. Z. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.206 · Cited by 1,024
Ascierto, P. A., McArthur, G. A., Dréno, B., Atkinson, V., Liszkay, G., Di Giacomo, A. M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30122-x · Cited by 1,022
Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody
Miller, R. A., Maloney, D. G., Warnke, R., & Levy, R. (1982) · New England Journal of Medicine · doi:10.1056/nejm198203043060906 · Cited by 985
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969
Ciardiello, F., Caputo, R., Bianco, R., Damiano, Pomatico, G., De Placido, S., Bianco, A. R., & Tortora, G. (2000) · PubMed · Cited by 943
Assessment of the Evolution of Cancer Treatment Therapies
Arruebo, M., Vilaboa, N., Sáez-Gutierrez, B., Lambea, J., Tres, A., Valladares, M., & González-Fernández, Á. (2011) · Cancers · doi:10.3390/cancers3033279 · Cited by 931
Gordon, M. S., Margolin, K., Talpaz, M., Sledge, G. W., Holmgren, E., Benjamin, R., Stalter, S., Shak, S., & Adelman, D. C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.843 · Cited by 913
Coiffier, B., Haïoun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D. D. F., Johnson, P., Lister, A., Feuring‐Buske, M., Radford, J. A., et al. (1998) · PubMed · doi:10.1182/blood.v92.6.1927 · Cited by 893
Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.124 · Cited by 872
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
The Pharmacology and Clinical Use of Methotrexate
Jolivet, J., Cowan, K. H., Curt, G. A., Clendeninn, N. J., & Chabner, B. A. (1983) · New England Journal of Medicine · doi:10.1056/nejm198311033091805 · Cited by 786
Maloney, D., Liles, T., Czerwinski, D., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A., & Levy, R. (1994) · Blood · doi:10.1182/blood.v84.8.2457.2457 · Cited by 762
New antibiotics, bleomycin A and B.
Umezawa, H., Maeda, K., Takeuchi, T., & Okami, Y. (1966) · PubMed · Cited by 725
The Edwin Smith Surgical Papyrus
Breasted, J. H. (1931) · September/Oktober 1931 · doi:10.1515/9783112615263-011 · Cited by 724
Therapeutic Radiopharmaceuticals
Volkert, W. A., & Hoffman, T. J. (1999) · Chemical Reviews · doi:10.1021/cr9804386 · Cited by 724
GOODMAN, L. S. (1946) · Journal of the American Medical Association · doi:10.1001/jama.1946.02870380008004 · Cited by 700
Tuveson, D. A., Willis, N. A., Jacks, T., Griffin, J. D., Singer, S., Fletcher, C. D., Fletcher, J. A., & Demetri, G. D. (2001) · Oncogene · doi:10.1038/sj.onc.1204704 · Cited by 695
Phase II Trial of Sorafenib in Advanced Thyroid Cancer
Gupta-Abramson, V., Troxel, A. B., Nellore, A., Puttaswamy, K., Redlinger, M., Ransone, K., Mandel, S. J., Flaherty, K. T., Loevner, L. A., O'Dwyer, P. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3279 · Cited by 680
Anthrazykline in der Krebstherapie: Ein Überblick
Hortobágyi, G. N. (1997) · Drugs · doi:10.2165/00003495-199700544-00003 · Cited by 678
Bleomycins: towards better therapeutics
Chen, J., & Stubbe, J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1547 · Cited by 664
Remaining mysteries of molecular biology: the role of polyamines in the cell
Miller-Fleming, L., Olin-Sandoval, V., Campbell, K., & Ralser, M. (2015) · Journal of Molecular Biology · doi:10.1016/j.jmb.2015.06.020 · Cited by 658
Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Hartmann, J., Haap, M., Kopp, H.-G., & Lipp, H.-P. (2009) · Current Drug Metabolism · doi:10.2174/138920009788897975 · Cited by 630
Adriamycin, 14‐hydroxydaimomycin, a new antitumor antibiotic from S. Peucetius var. caesius
Arcamone, F., Cassinelli, G., Fantini, G., Grein, A., Orezzi, P., Pol, C., & Spalla, C. (1969) · Biotechnology and Bioengineering · doi:10.1002/bit.260110607 · Cited by 622
Trastuzumab emtansine: mechanisms of action and drug resistance
Barok, M., Joensuu, H., & Isola, J. (2014) · Breast Cancer Research · doi:10.1186/bcr3621 · Cited by 595
Cutaneous melanoma: From pathogenesis to therapy (Review)
Leonardi, G., Falzone, L., Salemi, R., Zangh�, A., Spandidos, D., Mccubrey, J., Candido, S., & Libra, M. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4287 · Cited by 588
Self-citationThe reaction of mono- and di-functional alkylating agents with nucleic acids
Brookes, P., & Lawley, P. (1961) · Biochemical Journal · doi:10.1042/bj0800496 · Cited by 585
Kochenderfer, J. N., Somerville, R. P. T., Lu, T., Shi, V., Bot, A., Rossi, J., Xue, A., Goff, S. L., Yang, J. C., Sherry, R. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3024 · Cited by 569
Barker, A. J., Gibson, K. H., Grundy, W., Godfrey, A. A., Barlow, J. J., Healy, M. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Scarlett, L., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00344-4 · Cited by 569
Nanoparticle-assisted Combination Therapies for Effective Cancer Treatment
Hu, C.-M. J., Aryal, S., & Zhang, L. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.13 · Cited by 564
THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS.
JOHNSON, I. S., Jg, A., Gorman, M., & Jp, B. (1963) · PubMed · Cited by 564
The anthracyclines: will we ever find a better doxorubicin?
Weiss, R. B. (1992) · PubMed · Cited by 558
Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H. S., Sledge, G., Aktan, G., Ellis, C., Florance, A., Vukelja, S., Bischoff, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6725 · Cited by 547
Röntgen, W. C. (1896) · Science · doi:10.1126/science.3.59.227 · Cited by 543
Frenel, J.-S., Le Tourneau, C., O’Neil, B., Ott, P. A., Piha-Paul, S. A., Gomez-Roca, C., van Brummelen, E. M. J., Rugo, H. S., Thomas, S., Saraf, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.5471 · Cited by 531
Mounier, N. (2003) · Blood · doi:10.1182/blood-2002-11-3442 · Cited by 513
History of Cancer, Ancient and Modern Treatment Methods
Sudhakar, A. (2009) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.100000e2 · Cited by 504
Fiedler, W., Serve, H., Döhner, H., Schwittay, M., Ottmann, O. G., O'Farrell, A.-M., Bello, C. L., Allred, R., Manning, W. C., Cherrington, J. M., et al. (2005) · Blood · doi:10.1182/blood-2004-05-1846 · Cited by 490
Engineering CAR-T cells: Design concepts
Srivastava, S., & Riddell, S. R. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.06.004 · Cited by 485
Adjuvant Methotrexate and Citrovorum-Factor Treatment of Osteogenic Sarcoma
Jaffe, N., Frei, E., Traggis, D., & Bishop, Y. (1974) · New England Journal of Medicine · doi:10.1056/nejm197411072911902 · Cited by 483
Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.
Bissery, M.-C., Guénard, D., Guéritte, F., & Lavelle, F. (1991) · PubMed · Cited by 481
Robert, F., Ezekiel, M. P., Spencer, S. A., Meredith, R. F., Bonner, J. A., Khazaeli, M. B., Saleh, M. N., Carey, D., LoBuglio, A. F., Wheeler, R. H., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3234 · Cited by 474
Vokes, E. E., Ready, N., Felip, E., Horn, L., Burgio, M. A., Antonia, S. J., Arén Frontera, O., Gettinger, S., Holgado, E., Spigel, D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy041 · Cited by 464
LoRusso, P. M., Weiss, D., Guardino, E., Girish, S., & Sliwkowski, M. X. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0762 · Cited by 444
Lilenbaum, R. C., Herndon, J. E., List, M. A., Desch, C., Watson, D. M., Miller, A. A., Graziano, S. L., Perry, M. C., Saville, W., Chahinian, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.172 · Cited by 444
Cohen, M. H., Farrell, A., Justice, R., & Pazdur, R. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0255 · Cited by 426
Yu, K., Toral-Barza, L., Discafani, C., Zhang, W. G., Skotnicki, J., Frost, P., & Gibbons, J. J. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080249 · Cited by 420
Nadler, L. M., Stashenko, P., Hardy, R., Kaplan, W. D., Button, L. N., Kufe, D. W., Antman, K. H., & Schlossman, S. F. (1980) · PubMed · Cited by 413
ROLE OF CHANCE OBSERVATIONS IN CHEMOTHERAPY: VINCA ROSEA*
Noble, R. L., Beer, C. T., & Cutts, J. H. (1958) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1958.tb54906.x · Cited by 407
Polyamine Metabolism: A Potential Therapeutic Target in Trypanosomes
Bacchi, C. J., Nathan, H. C., Hutner, S. H., McCann, P. P., & Sjoerdsma, A. (1980) · Science · doi:10.1126/science.6775372 · Cited by 393
Monoclonal Antibodies for Cancer Therapy
(2012) · SpringerReference · doi:10.1007/springerreference_303431 · Cited by 393
Hurvitz, S. A., Dirix, L., Kocsis, J., Bianchi, G. V., Lu, J., Vinholes, J., Guardino, E., Song, C., Tong, B., Ng, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.9694 · Cited by 392
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
Rossari, F., Minutolo, F., & Orciuolo, E. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0624-2 · Cited by 371
Mueller, K. T., Maude, S. L., Porter, D. L., Frey, N., Wood, P., Han, X., Waldron, E., Chakraborty, A., Awasthi, R., Levine, B. L., et al. (2017) · Blood · doi:10.1182/blood-2017-06-786129 · Cited by 362
Camptothecin and Taxol: Historic Achievements in Natural Products Research
Oberlies, N. H., & Kroll, D. J. (2004) · Journal of Natural Products · doi:10.1021/np030498t · Cited by 353
An overview of small-molecule inhibitors of VEGFR signaling
Ivy, S. P., Wick, J. Y., & Kaufman, B. M. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.130 · Cited by 350
Imbert, T. F. (1998) · Biochimie · doi:10.1016/s0300-9084(98)80004-7 · Cited by 350
Brahmer, J. R., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30690-3 · Cited by 348
The initial clinical trial of nitrogen mustard
Gilman, A. (1963) · The American Journal of Surgery · doi:10.1016/0002-9610(63)90232-0 · Cited by 338
Mita, A. C., Denis, L. J., Rowinsky, E. K., DeBono, J. S., Goetz, A. D., Ochoa, L., Forouzesh, B., Beeram, M., Patnaik, A., Molpus, K., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0596 · Cited by 332
Hainsworth, J. D., Litchy, S., Shaffer, D. W., Lackey, V. L., Grimaldi, M., & Greco, F. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.191 · Cited by 330
CRISPR/Cas9 for cancer research and therapy
Zhan, T., Rindtorff, N., Betge, J., Ebert, M. P., & Boutros, M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.04.001 · Cited by 328
Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
Shepard, H. M., Lewis, G. D., Sarup, J. C., Fendly, B. M., Maneval, D., Mordenti, J., Figari, I., Kotts, C. E., Palladino, M. A., Ullrich, A., et al. (1991) · Journal of Clinical Immunology · doi:10.1007/bf00918679 · Cited by 294
The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0
Silberstein, E. B., Alavi, A., Balon, H. R., Clarke, S. E. M., Divgi, C., Gelfand, M. J., Goldsmith, S. J., Jadvar, H., Marcus, C. S., Martin, W. H., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.105148 · Cited by 287
Milojkovic, D., & Apperley, J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1068 · Cited by 265
Fessas, P., Lee, H., Ikemizu, S., & Janowitz, T. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.06.002 · Cited by 255
Tsimberidou, A.-M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2861-1 · Cited by 249
Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.
Marco, A. D., Gaetani, M., & Scarpinato, B. (1969) · PubMed · Cited by 243
Dagher, R., Cohen, M., Williams, G., et al. (2002) · PubMed · Cited by 237
Aboud-Pirak, E., Hurwitz, E., Pirak, M., Bellot, F., Schlessinger, J., & Sela, M. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.20.1605 · Cited by 231
Cancer gene therapy: hard lessons and new courses
Vile, R. G., Russell, S. J., & Lemoine, N. R. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301084 · Cited by 231
The reaction of mustard gas with nucleic acids in vitro and in vivo
Brookes, P., & Lawley, P. D. (1960) · Biochemical Journal · doi:10.1042/bj0770478 · Cited by 229
&NA;, &. (1997) · Journal of Immunotherapy · doi:10.1097/00002371-199705000-00007 · Cited by 228
The Emperor of All Maladies: A Biography of Cancer
Mehta, P. (2011) · JAMA · doi:10.1001/jama.2011.798 · Cited by 225
A brief history of cancer: Age‐old milestones underlying our current knowledge database
Faguet, G. B. (2014) · International Journal of Cancer · doi:10.1002/ijc.29134 · Cited by 220
Taxane anticancer agents: a patent perspective
Ojima, I., Lichtenthal, B., Lee, S., Wang, C., & Wang, X. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1111872 · Cited by 217
(1949) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1949.tb68027.x · Cited by 215
Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs.
Chen, J.-G., & Horwitz, S. B. (2002) · PubMed · Cited by 212
Frei, E. (1985) · PubMed · Cited by 208
Haanen, J. B. A. G., & Robert, C. (2015) · Progress in Tumor Research · doi:10.1159/000437178 · Cited by 208
Allosteric small-molecule kinase inhibitors
Wu, P., Clausen, M. H., & Nielsen, T. E. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.10.002 · Cited by 204
Hahn, E. A., Glendenning, G. A., Sorensen, M. V., Hudgens, S. A., Druker, B. J., Guilhot, F., Larson, R. A., O’Brien, S. G., Dobrez, D. G., Hensley, M. L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.154 · Cited by 204
Ansell, S. M., Inwards, D. J., Rowland, K. M., Flynn, P. J., Morton, R. F., Moore, D. F., Kaufmann, S. H., Ghobrial, I., Kurtin, P. J., Maurer, M., et al. (2008) · Cancer · doi:10.1002/cncr.23580 · Cited by 203
Antimitotic drugs in the treatment of cancer
van Vuuren, R. J., Visagie, M. H., Theron, A. E., & Joubert, A. M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2903-8 · Cited by 200
NITROGEN MUSTARDS IN THE TREATMENT OF NEOPLASTIC DISEASE: Official Statement
RHOADS, C. P. (1946) · Journal of the American Medical Association · doi:10.1001/jama.1946.02870250010003 · Cited by 198
Adams, V. R., & Leggas, M. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.022 · Cited by 197
Therapy of Choriocarcinoma and Related Trophoblastic Tumors with Folic Acid and Purine Antagonists
Li, M. C., Hertz, R., & Bergenstal, D. M. (1958) · New England Journal of Medicine · doi:10.1056/nejm195807102590204 · Cited by 189
Bevacizumab: A Review of Its Use in Advanced Cancer
Keating, G. M. (2014) · Drugs · doi:10.1007/s40265-014-0302-9 · Cited by 177
New antimetabolites in cancer chemotherapy and their clinical impact
Kaye, S. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.747 · Cited by 177
Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
Peralba, J. M., deGraffenried, L. A., Friedrichs, W. E., Fulcher, L. C., Grünwald, V., Weiss, G. R., & Hidalgo, M. M. (2003) · PubMed · Cited by 175
Mechanisms of mTOR inhibitor resistance in cancer therapy
Carew, J. S., Kelly, K. R., & Nawrocki, S. T. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0167-8 · Cited by 161
Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation
Deloch, L., Derer, A., Hartmann, J., Frey, B., Fietkau, R., & Gaipl, U. S. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00141 · Cited by 161
Tragedy, Perseverance, and Chance — The Story of CAR-T Therapy
Rosenbaum, L. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1711886 · Cited by 153
Forrer, F., Uusijärvi, H., Storch, D., Maëcke, H. R., & Mueller‐Brand, J. (2005) · PubMed · Cited by 146
The Sodium Iodide Symporter and Its Potential Role in Cancer Therapy
Spitzweg, C., Harrington, K. J., PINKE, L. A., Vile, R. G., & Morris, J. C. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7641 · Cited by 141
CETUXIMAB: From Bench to Bedside
Vincenzi, B., Zoccoli, A., Pantano, F., Venditti, O., & Galluzzo, S. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910790980241 · Cited by 141
Imidazoles. I. Coupling Reactions of 5-Diazoimidazole-4-carboxamide1,2
Shealy, Y. F., Krauth, C. A., & Montgomery, J. A. J. (1962) · The Journal of Organic Chemistry · doi:10.1021/jo01053a060 · Cited by 139
From old alkylating agents to new minor groove binders
Puyo, S., Montaudon, D., & Pourquier, P. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.07.006 · Cited by 139
HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer
Harbeck, N., Beckmann, M. W., Rody, A., Schneeweiß, A., Müller, V., Fehm, T. N., Marschner, N. W., Gluz, O., Schrader, I., Heinrich, G., et al. (2013) · Breast Care · doi:10.1159/000346837 · Cited by 139
Diaby, V., Tawk, R. H., Sanogo, V., Xiao, H., & Montero, A. J. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3383-6 · Cited by 139
Hasskarl, J. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_8 · Cited by 137
THE CHEMISTRY AND BIOCHEMISTRY OF PURINE ANALOGS
Hitchings, G. H., & Elion, G. B. (1954) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1954.tb40008.x · Cited by 136
Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate
Anafi, M., Gazit, A., Zehavi, A., Ben‐Neriah, Y., & Levitzki, A. (1993) · Blood · doi:10.1182/blood.v82.12.3524.3524 · Cited by 133
The combination of curcumin and 5-fluorouracil in cancer therapy
Wei, Y., Yang, P., Cao, S., & Zhao, L. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0979-x · Cited by 124
Daunomycin: A New Antibiotic with Antitumor Activity
Marco, A. D., Gaetani, M., Dorigotti, L., Soldati, M., & Bellini, O. (1963) · Tumori Journal · doi:10.1177/030089166304900305 · Cited by 122
Voigtlaender, M., Schneider‐Merck, T., & Trepel, M. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_2 · Cited by 121
Targeting mTOR Pathways in Human Malignancies
Fasolo, A., & Sessa, C. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212800626210 · Cited by 112
Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment
Jadvar, H. (2017) · American Journal of Roentgenology · doi:10.2214/ajr.17.18264 · Cited by 112
Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes, E. E., & Chu, E. (2006) · PubMed · Cited by 106
The treatment of cancer in Greek antiquity
Karpozilos, A., & Pavlidis, N. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.04.036 · Cited by 105
Epidemiologic study of tumors in dinosaurs
Rothschild, B. M., Tanke, D. H., Helbling, M., & MARTIN, L. D. (2003) · Die Naturwissenschaften · doi:10.1007/s00114-003-0473-9 · Cited by 104
Monoclonal Antibodies for the Treatment of Cancer
Pento, J. T. (2017) · Anticancer Research · doi:10.21873/anticanres.12040 · Cited by 104
Jayaraman, T., & Marks, A. R. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74403-2 · Cited by 101
DNA and chromosome damage induced by bleomycin in mammalian cells: An update
Bolzán, A. D., & de Bianchi, M. S. A. (2018) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2018.02.003 · Cited by 100
Salemi, R., Falzone, L., Madonna, G., Polesel, J., Cinà, D., Mallardo, D., Ascierto, P. A., Libra, M., & Candido, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00856 · Cited by 91
Self-citationGittelman, M. (2016) · Research Policy · doi:10.1016/j.respol.2016.01.007 · Cited by 87
Waller, C. F. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91439-8_1 · Cited by 83
Antibodies directed against receptor tyrosine kinases
Fauvel, B., & Yasri, A. (2014) · mAbs · doi:10.4161/mabs.29089 · Cited by 81
Intensive Combination Chemotherapy and X-Irradiation in Hodgkin's Disease
DeVita, V. T., DeVita-Raeburn, E., & Moxley, J. H. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0470 · Cited by 80
Harsh, S., Adhikari, A., Parazuli, P., Pathak, R., Khadga, P. K., & Sharma, S. (2015) · Journal of Advances in Internal Medicine · doi:10.3126/jaim.v4i1.14173 · Cited by 78
O’Mahony, D., & Bishop, M. R. (2006) · Frontiers in bioscience · doi:10.2741/1909 · Cited by 77
Muth, A., Madan, M., Archer, J. J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401174a · Cited by 73
Nonviral Gene Therapy for Cancer: A Review
Hidai, C., & Kitano, H. (2018) · Diseases · doi:10.3390/diseases6030057 · Cited by 72
Chen, H.-X., Gore‐Langton, R. E., & Cheson, B. D. (2001) · PubMed · Cited by 69
Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents
O’Reilly, T., McSheehy, P. M. J., Kawai, R., Kretz, O., McMahon, L. M., Brueggen, J., Bruelisauer, A., Gschwind, H.-P., ALLEGRINI, P. R., & Lane, H. A. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1068-8 · Cited by 66
Niculescu‐Duvaz, I. (2010) · PubMed · Cited by 65
Using cyclophosphamide in inflammatory rheumatic diseases
Brummaier, T., Pohanka, E., Studnicka-Benke, A., & Pieringer, H. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.02.008 · Cited by 62
Damiani, E., & WALLACE, H. M. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7398-9_39 · Cited by 62
A note from history: Landmarks in history of cancer, Part 6
Hajdu, S. I., & Vadmal, M. S. (2013) · Cancer · doi:10.1002/cncr.28319 · Cited by 60
Cyclophosphamide in dermatology
Kim, J., & Chan, J. J. (2016) · Australasian Journal of Dermatology · doi:10.1111/ajd.12406 · Cited by 56
Anderson, P. M., Subbiah, V., & ROHREN, E. M. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_16 · Cited by 55
The early history of the biological alkylating agents, 1918–1968
Brookes, P. (1990) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(90)90145-t · Cited by 53
Faiena, I., Cummings, A. L., Crosetti, A. M., Pantuck, A. J., Chamie, K., & Drakaki, A. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s141491 · Cited by 53
Sodium Iodide Symporter and the Radioiodine Treatment of Thyroid Carcinoma
Chung, J.-K., Youn, H. W., Kang, J. H., Lee, H., & Kang, K. W. (2010) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-009-0016-1 · Cited by 52
Observations on the anticancer activity of 6-mercaptopurine.
He, S., Thomson, Elion, G. B., & Hitchings, G. H. (1954) · PubMed · Cited by 49
(2016) · Profiles of Drug Substances, Excipients and Related Methodology · doi:10.1016/bs.podrm.2015.12.002 · Cited by 48
Treatment of Bone Metastasis with Bone-Targeting Radiopharmaceuticals
Choi, J. Y. (2018) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-017-0509-2 · Cited by 48
Emerging targeted therapies for melanoma treatment (Review)
RUSSO, A., Ficili, B., Candido, S., Pezzino, F. M., Guarneri, C., Biondi, A., Travali, S., McCubrey, J. A., Spandidos, D. A., & Libra, M. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2481 · Cited by 47
Self-citationThe development of CAR design for tumor CAR-T cell therapy
Xu, D., Jin, G., Chai, D., Zhou, X., Gu, W., Chong, Y., Song, J., & Zheng, J. (2018) · Oncotarget · doi:10.18632/oncotarget.24179 · Cited by 47
The application of monoclonal antibodies in cancer diagnosis
Zhang, X., Soori, G. S., Dobleman, T. J., & Xiao, G. G. (2013) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.866039 · Cited by 46
Sakamuri, D., Glitza, I. C., Cuellar, S. L. B., Subbiah, V., Fu, S., Tsimberidou, A. M., Wheler, J. J., Hong, D. S., Naing, A., Falchook, G. S., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0673 · Cited by 45
Cited by
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer
Abu Samaan, T. M., Samec, M., Liskova, A., Kubatka, P., & Büsselberg, D. (2019) · Biomolecules · doi:10.3390/biom9120789 · Cited by 569
Sex disparities matter in cancer development and therapy
Haupt, S., Caramia, F., Klein, S. L., Rubin, J. B., & Haupt, Y. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00348-y · Cited by 331
Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities
Shemesh, C. S., Hsu, J. C., Hosseini, I., Shen, B.-Q., Rotte, A., Twomey, P., Girish, S., & Wu, B. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.038 · Cited by 286
Metadata
- Authors
- Falzone, L., Salomone, S., & Libra, M.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-11-13
- Volume
- 9
- Pages
- 1300-1300
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2900960361
- Cited by
- 908
- References
- 228
- FWCI
- 50.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.